‘Target-high but uptake-defective’ state identified in ADC resistance
· anette breindl
AI Briefing
- • Researchers identify a "target-high but uptake-defective" state in ADC resistance to Padcev.
- • This state affects Padcev's ability to target Nectin-4 in urothelial cancer cells.
- • The finding may have implications for ADCs more broadly, including other cancer treatments.
Source Summary
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer’s top 10 medicines and vaccines, generating $1.94 billion in 2025.
Advertisement